Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria in children: clinical cases
https://doi.org/10.17650/2311-1267-2016-3-4-77-80
Abstract
Paroxysmal nocturnal hemoglobinuria (PNH) at children presents at children rarely in comparison with adults, but clinical presentation characterized by the same symptoms and complications like at the adult population of patients. Children present with chronic hemolysis, thrombosis, abdominal pain, infection complications, fatigue, decreasing of quality of life. In this case, the feature of PNH at children is predominant combination of diseases with bone marrow failure (most common, aplastic anemia) and relatively rare hemoglobinuria, what can complicate in-time diagnosing. Blood testing with the help of flow cytometry allows establishing diagnosis and risking groups for PNH determination presented in the international guidelines. In-time diagnostics of diseases is very important for treatment tactics chosen and prognosis, and gain the high importance with the appearance of possibility of pathogenetic therapy by eculizumab medication. Eculizumab is the humanized monoclonal antibody which inhibits the activity of complement system and prevents development of chronic intravascular hemolysis in case of PNH. Effectiveness and safety of eculizumab were proven in clinical studies both for children and adults. This article presents own experience of treatment of 2 children with PNH on the base of Uliyanovsk Regional Clinical Hospital.
About the Author
V. N. Timofeeva
Ulyanovsk Regional Children's Clinical Hospital named after a public and political figure of the Ulyanovsk region Yu.F. Goryachev;
Russian Federation
42 Radishcheva St., Ulyanovsk, 432011
Russian Federation
42 Radishcheva St., Ulyanovsk, 432011
References
1. Hill A., Platts P. J., Smith A. et al. The incidence and prevalence of Paroxysmal Nocturnal Haemoglobinuria (PNH) and survival of patients in Yorkshire. Blood 2006;108(11):290 a. Abstract 985.
2. Rosse W., Ware R.E. The molecular basis of paroxysmal nocturnal hemoglobinuria. Blood 1995;86(9):3277−86.
3. Rollins S.A., Sims P.J. The complementinhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol 1990;144:3478–83.
4. Brodsky R.A. Paroxysmal nocturnal hemoglobinuria. In: Hoffman R., Benz E. et al. Hematology: Basic Principles and Practice. Churchill Livingstone, Philadelphia, 2005. Pp. 419–427.
5. Moyo V.M., Mukhina G.L., Garrett E.S., Brodsky R.A. Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays. Br J Haematol 2004;126(1):133–8.
6. Nishimura J., Kanakura Y., Ware R.E. et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore) 2004;83(3):193–207.
7. Hill A., Kelly R.J., Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood 2013;121(25):4985–96.
8. Poulou L.S., Xila V., Rokas G.I. et al. Temporal trends in mortality rates from visceral vein thrombosis in paroxysmal nocturnal haemoglobinuria: An optimistic view. Thromb Haemost 2008;99(3):642–5.
9. Nath K.A., Vercellotti G.M., Grande J.P. et al. Heme protein-induced chronic renal inflammation: suppressive effect of induced heme oxygenase-1. Kidney Intern 2001;59:106–17.
10. Kim J.S., Jang J.H., Lee J.W. et al. Renal impairment is a risk factor for early mortality in patients with paroxysmal nocturnal hemoglobinuria (PNH). In: Posters of the 16th Congress of the European Hematology Association; June 9–12, 2011; London, United Kingdom. Abstraсt 027l.
11. Borowitz M.J., Craig F.E., Digiuseppe J.A. et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin Cytom 2010;78(4):211–30.
12. Кулагин А.Д., Лисуков И.А., Птушкин В.В. и др. Национальные клинические рекомендации по диагностике и лечению пароксизмальной ночной гемоглобинурии. Клиническая фармакология и терапия 2015;24(1):18–26. [Kulagin A.D., Lisukov I.A., Ptushkin V.V. et al. National clinical guidelines for the diagnosis and treatment of paroxysmal nocturnal hemoglobinuria. Klinicheskaya farmakologiya i terapiya = Clinical Pharmacology and Therapy 2015;24(1):18–26. (In Russ.)].
13. Naithani R., Mahapatra M., Dutta P. et al. Paroxysmal nocturnal hemoglobinuria in childhood and adolescence – A retrospective analysis of 18 cases. Ind J Pediatr 2008;75:575–8.
14. Curran K.J., Kernan N.A., Prockop S.E. et al. Paroxysmal nocturnal hemoglobinuria in pediatric patients. Pediatr Blood Cancer 2012;59:525–9.
15. Reiss U.M., Schwartz J., Sakamoto K.M. et al. Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria. Pediatr Blood Cancer 2014;61(9):1544–50.
16. Зырянов С.К., Моисеев С.В. Клиническая фармакология и эффективность экулизумаба в лечении пароксизмальной ночной гемоглобинурии и атипичного гемолитико-уремического синдрома. Клиническая фармакология и терапия 2014;23(1):81–6. [Zyryanov S.K., Moiseev S.V. Clinical pharmacology and efficacy of eculizumabin patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Klinicheskaya farmakologiya i terapiya = Clinical Pharmacology and Therapy 2014;23(1):81–6. (In Russ.)].
Review
For citations:
Timofeeva V.N. Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria in children: clinical cases. Russian Journal of Pediatric Hematology and Oncology. 2016;3(4):77-80. (In Russ.) https://doi.org/10.17650/2311-1267-2016-3-4-77-80
Views:
1261
Email this article 